26
Feb
This devastating epidemic in nonendemic areas highlights an urgent need for the development of therapeutics against emerging and reemerging filoviruses. Monoclonal antibodies (mAbs) show great promise for development of effective filovirus antibody treatments [3]. Democratic Republic of Congo [1]. Cumulatively, these outbreaks resulted in a case-fatality rate of 33.7%, which is comparable to that of Ebola disease (EBOV) infections, including the Western African epidemic of 2013C2016 (41.4%) [2]. This devastating epidemic in nonendemic areas shows an urgent need for the development of therapeutics against growing and reemerging filoviruses. Monoclonal antibodies (mAbs) show great promise for development of effective filovirus LY2109761…